Skip to main content
Fig. 5 | Cellular & Molecular Biology Letters

Fig. 5

From: Empagliflozin improves renal ischemia–reperfusion injury by reducing inflammation and enhancing mitochondrial fusion through AMPK–OPA1 pathway promotion

Fig. 5

AMPK inhibitor blocked the promotion of OPA1 by empagliflozin. a H/R HK-2 cells were constructed, and supplemented with empagliflozin or PBS along with AMPK inhibitor Dorsomorphin or DMSO. After 24 h culture, RNA was extracted and OPA1 expression was detected by quantitative PCR. b After the same treatment as a, total protein samples were extracted, and immunoblot western blot was performed to detect OPA1 levels. The experiments were repeated independently at least three times, and the data were presented as the means ± SEM. Statistical significance with respect to control was marked with *P < 0.05, **P < 0.01, or ***P < 0.001

Back to article page